Regeneron says COVID cocktail prevents, treats virus in animals – Seeking Alpha

The lead scientists likewise say the animals did disappoint any indications of increased viral load or worsening of pathology after treatment, an essential safety signal that recommends it will not aggravate signs in people.

Regeneron already has actually released late-stage clinical trials in people to examine the antibody treatments capability to avoid and treat COVID-19.

The company states its REGN-COV2 cocktail of two monoclonal antibodies had the ability to “nearly entirely obstruct establishment of virus infection” in the animal research study and decreased infection in a 2nd study in which animals were infected with a much greater level of the virus.

Regeneron Pharmaceuticals (NASDAQ: REGN) says its COVID-19 antibody drug mix under advancement both treated the illness and avoided in rhesus macaques and hamsters, stimulating hope that it might work for people.

prophylaxis study

treatment setting